FibroGen (FGEN) Competitors $5.62 +0.25 (+4.66%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$5.60 -0.02 (-0.36%) As of 07/8/2025 05:09 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock FGEN vs. FBRX, CHRS, CLLS, CRBP, CLYM, ZNTL, JSPR, EXOZ, TCRX, and ELUTShould you be buying FibroGen stock or one of its competitors? The main competitors of FibroGen include Forte Biosciences (FBRX), Coherus Oncology (CHRS), Cellectis (CLLS), Corbus Pharmaceuticals (CRBP), Climb Bio (CLYM), Zentalis Pharmaceuticals (ZNTL), Jasper Therapeutics (JSPR), eXoZymes (EXOZ), TScan Therapeutics (TCRX), and Elutia (ELUT). These companies are all part of the "pharmaceutical products" industry. FibroGen vs. Its Competitors Forte Biosciences Coherus Oncology Cellectis Corbus Pharmaceuticals Climb Bio Zentalis Pharmaceuticals Jasper Therapeutics eXoZymes TScan Therapeutics Elutia FibroGen (NASDAQ:FGEN) and Forte Biosciences (NASDAQ:FBRX) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their institutional ownership, risk, earnings, valuation, media sentiment, profitability, analyst recommendations and dividends. Do analysts recommend FGEN or FBRX? FibroGen currently has a consensus price target of $250.00, indicating a potential upside of 4,348.40%. Forte Biosciences has a consensus price target of $61.00, indicating a potential upside of 388.78%. Given FibroGen's higher probable upside, analysts plainly believe FibroGen is more favorable than Forte Biosciences.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score FibroGen 0 Sell rating(s) 1 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.50Forte Biosciences 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Is FGEN or FBRX more profitable? Forte Biosciences has a net margin of 0.00% compared to FibroGen's net margin of -9.73%. FibroGen's return on equity of 0.00% beat Forte Biosciences' return on equity.Company Net Margins Return on Equity Return on Assets FibroGen-9.73% N/A -24.77% Forte Biosciences N/A -149.15%-114.25% Which has preferable earnings and valuation, FGEN or FBRX? Forte Biosciences has lower revenue, but higher earnings than FibroGen. FibroGen is trading at a lower price-to-earnings ratio than Forte Biosciences, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioFibroGen$29.62M0.77-$47.58M-$2.50-2.25Forte BiosciencesN/AN/A-$35.48M-$16.29-0.77 Do insiders and institutionals have more ownership in FGEN or FBRX? 72.7% of FibroGen shares are held by institutional investors. Comparatively, 77.6% of Forte Biosciences shares are held by institutional investors. 2.0% of FibroGen shares are held by insiders. Comparatively, 5.9% of Forte Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Which has more risk & volatility, FGEN or FBRX? FibroGen has a beta of 0.74, meaning that its share price is 26% less volatile than the S&P 500. Comparatively, Forte Biosciences has a beta of 2.97, meaning that its share price is 197% more volatile than the S&P 500. Does the media favor FGEN or FBRX? In the previous week, FibroGen had 2 more articles in the media than Forte Biosciences. MarketBeat recorded 2 mentions for FibroGen and 0 mentions for Forte Biosciences. FibroGen's average media sentiment score of 1.94 beat Forte Biosciences' score of 0.00 indicating that FibroGen is being referred to more favorably in the media. Company Overall Sentiment FibroGen Very Positive Forte Biosciences Neutral SummaryForte Biosciences beats FibroGen on 8 of the 15 factors compared between the two stocks. Get FibroGen News Delivered to You Automatically Sign up to receive the latest news and ratings for FGEN and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding FGEN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart FGEN vs. The Competition Export to ExcelMetricFibroGenMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$21.70M$2.39B$5.47B$8.95BDividend YieldN/A1.80%5.25%4.06%P/E Ratio-2.258.9827.0020.10Price / Sales0.77729.50435.75120.29Price / CashN/A159.8036.8257.86Price / Book-0.114.517.985.56Net Income-$47.58M$31.26M$3.16B$248.40M7 Day Performance7.05%3.57%2.40%4.67%1 Month Performance-29.64%1.28%2.19%6.64%1 Year Performance-73.21%1.08%33.82%21.31% FibroGen Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)FGENFibroGen4.6858 of 5 stars$5.62+4.7%$250.00+4,348.4%-72.2%$21.70M$29.62M-2.25570Positive NewsFBRXForte Biosciences2.54 of 5 stars$12.93+5.6%$61.00+371.8%+58,767.9%$85.08MN/A-0.795CHRSCoherus Oncology3.7126 of 5 stars$0.73-1.6%$4.68+540.4%-36.0%$84.78M$266.96M-0.65330Gap UpCLLSCellectis3.039 of 5 stars$1.53+5.2%$4.00+162.3%-20.3%$84.77M$47.63M-1.77290CRBPCorbus Pharmaceuticals3.8037 of 5 stars$6.90-6.8%$50.88+637.3%-85.2%$84.44MN/A-1.6440CLYMClimb Bio2.6249 of 5 stars$1.24+5.1%$9.00+625.8%N/A$83.80MN/A-0.529Positive NewsZNTLZentalis Pharmaceuticals1.5499 of 5 stars$1.16-1.7%$8.37+621.3%-69.6%$83.46M$67.43M-0.37160Gap UpJSPRJasper Therapeutics3.2926 of 5 stars$5.55+1.1%$59.25+967.6%-85.7%$83.36MN/A-1.0620Trending NewsAnalyst ForecastGap UpEXOZeXoZymesN/A$9.88-4.9%N/AN/A$82.70M$70K0.0029Gap DownHigh Trading VolumeTCRXTScan Therapeutics2.5944 of 5 stars$1.45+3.6%$7.80+437.9%-70.8%$82.06M$2.82M-1.33100News CoverageGap UpELUTElutia3.5754 of 5 stars$1.98-5.7%$8.00+304.0%-53.0%$81.41M$23.71M-1.03180Positive News Related Companies and Tools Related Companies Forte Biosciences Competitors Coherus Oncology Competitors Cellectis Competitors Corbus Pharmaceuticals Competitors Climb Bio Competitors Zentalis Pharmaceuticals Competitors Jasper Therapeutics Competitors eXoZymes Competitors TScan Therapeutics Competitors Elutia Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:FGEN) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersA grave, grave error.I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredThis Signal Only Flashes Once Every 4 Years – And It Just TriggeredThis same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBanks aren’t ready for this altcoin—are you?Our expert analysts have identified a $100 billion gap in the crypto market. Only one project is perfectly ...Crypto 101 Media | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredTrump’s New Order Could Boost Social Security Benefits by 400%If you collect—or plan to collect—Social Security, you need to see this. A new initiative tied to President...InvestorPlace | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding FibroGen, Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share FibroGen With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
